Analysis of declining efficacy outcomes between animal studies and human trials of acute stroke

Takeaway

  • There is a stepwise efficacy decline for acute stroke treatments from experimental studies to early clinical trials to Phase III clinical trials, which is explained by publication bias, noncompliance with quality criteria, significant differences in study design, and low power of experimental studies and early clinical trials.

Why this matters

  • A majority of acute stroke treatments that show promise in animal studies eventually fail in large clinical trials.

  • Further understanding this trend, and the factors contributing to it, will aid in the development of better clinical trials and, potentially, new treatments.